Pharmala Biotech Holdings Inc., a Canadian biotechnology company listed on the Canadian National Stock Exchange, has been actively engaged in the development and commercialization of novel therapeutic agents, with a primary focus on oncology. The company is renowned for its innovative approach to drug discovery, leveraging a robust portfolio of proprietary technologies and intellectual property rights in cancer biology. Pharmala’s mission is to transform patient outcomes by delivering breakthrough therapies that address unmet medical needs.
As of March 8, 2026, Pharmala Biotech has not issued any new public announcements. The most recent press release, dated February 23, 2026, was disseminated by Finanznachrichten.de. This announcement highlighted a significant supply contract with Amsterdam UMC for Pharmala’s LaNeo MDMA platform. Additionally, the company is continuing its work on single-capsule stability data, which is crucial for the advancement of its therapeutic offerings.
Financially, Pharmala Biotech’s stock has experienced fluctuations over the past year. As of March 5, 2026, the closing price was C$0.11. The stock reached its 52-week high of C$0.20 on March 23, 2025, and its 52-week low of C$0.085 on December 7, 2025. The company’s market capitalization stands at approximately 11,977,594 CAD. The price-to-earnings ratio is currently –5.39, indicating that the company is not generating positive earnings at this time. Meanwhile, the price-to-book ratio is 5.04, suggesting that the market values the company at roughly five times its book value.
Pharmala Biotech operates through two main divisions: Research and Development, and Commercialization. The company is committed to achieving sustainable growth by fostering long-term partnerships with other biotechnology firms, researchers, and stakeholders within the healthcare industry. This strategic approach aims to enhance its capabilities in drug discovery and development, ultimately contributing to its mission of delivering innovative therapies to patients in need.
